We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
Read MoreHide Full Article
Key Takeaways
Summit Therapeutics shares jumped after AstraZeneca agreed to invest $2 billion in the company.
The deal will fund ivonescimab development and clinical studies with AstraZeneca's oncology medicines.
Summit's cash position could rise sharply as it advances multiple phase III ivonescimab studies.
Shares of Summit Therapeutics (SMMT - Free Report) rose 22% in pre-market trading on Tuesday after it announced that AstraZeneca (AZN - Free Report) had agreed to invest $2 billion in the company to accelerate development of its lead pipeline drug, ivonescimab.
The deal is structured as a strategic equity investment, with AstraZeneca purchasing approximately 108,955 shares of preferred stock convertible into shares of Summit’s common stock at a 1:1,000 ratio. At the conversion ratio, the investment represents an effective common-stock price of $18.36 per share, roughly 19% above Summit's closing price on Sept. 28.
Once completed, AstraZeneca will hold rights equivalent to about 12% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis. The transaction is expected to close by the end of the week, subject to customary conditions.
SMMT’s Deal With AZN Extends Beyond Equity Stake
The equity investment is accompanied by two separate clinical-development arrangements between Summit and AstraZeneca, both centered on combining ivonescimab with AstraZeneca's oncology portfolio.
Under the first agreement, the companies will evaluate ivonescimab in combination with AstraZeneca's Claudin 18.2-targeting antibody-drug conjugate (ADC), sonesitatug vedotin (sone-ve), for gastrointestinal cancers. The companies intend to initiate clinical studies of the combination imminently.
The companies have also signed a non-binding memorandum of understanding for a broader global development program that would evaluate ivonescimab in combination with multiple AstraZeneca cancer medicines, including additional ADCs.
Importantly, the arrangements are non-exclusive, with each company retaining its existing development and commercial rights to its respective molecule. For the combination studies, the companies will contribute their respective medicines and jointly share the costs of clinical development.
SMMT’s Stock Performance
Year to date, the company’s shares have lost about 12% compared with the industry’s 4% decline.
Image Source: Zacks Investment Research
Deal Gives Summit More Financial Flexibility
The $2 billion investment should significantly strengthen Summit's balance sheet as it expands the development of ivonescimab. The company had about $691 million in cash and short-term investments as of June 30, 2026, meaning the AstraZeneca investment is nearly three times its existing liquidity.
The additional funds are expected to give Summit greater flexibility to fund multiple clinical programs and reduce its near-term reliance on the capital markets. The transaction also provides a notable external endorsement of Summit's strategy, although the investment does not eliminate the clinical and regulatory risks associated with ivonescimab. The conversion would not only increase SMMT’s share count but also result in dilution for existing shareholders.
For AstraZeneca, the deal provides an opportunity to test ivonescimab alongside its own oncology portfolio, without acquiring Summit or obtaining exclusive rights to ivonescimab.
Summit’s Progress With Ivonescimab
Ivonescimab is a bispecific antibody designed to simultaneously target PD-1 and VEGF, two pathways that are already established targets in cancer treatment. The drug was originally developed by Akeso, with Summit holding exclusive development and commercialization rights across major markets outside China. Akeso retains the rights to market the drug in China, where it is currently approved to treat multiple non-small cell lung cancer (NSCLC) indications.
An FDA filing is currently under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment. A final decision is expected by Nov. 14, 2026.
Summit is pursuing a broad global development program for ivonescimab. It is advancing the drug across multiple phase III studies — HARMONi-3 in first-line metastatic NSCLC, HARMONi-7 in first-line metastatic PD-L1 high (≥50%) NSCLC and HARMONi-GI3 in first-line metastatic colorectal cancer. Last month, the company initiated the phase II/III HARMONi-GU1 study, evaluating ivonescimab plus Pfizer’s (PFE - Free Report) /Astellas’ Padcev as first-line treatment for advanced urothelial or bladder cancer.
View the Zacks #1 Rank List
Image: Bigstock
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
Key Takeaways
Shares of Summit Therapeutics (SMMT - Free Report) rose 22% in pre-market trading on Tuesday after it announced that AstraZeneca (AZN - Free Report) had agreed to invest $2 billion in the company to accelerate development of its lead pipeline drug, ivonescimab.
The deal is structured as a strategic equity investment, with AstraZeneca purchasing approximately 108,955 shares of preferred stock convertible into shares of Summit’s common stock at a 1:1,000 ratio. At the conversion ratio, the investment represents an effective common-stock price of $18.36 per share, roughly 19% above Summit's closing price on Sept. 28.
Once completed, AstraZeneca will hold rights equivalent to about 12% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis. The transaction is expected to close by the end of the week, subject to customary conditions.
SMMT’s Deal With AZN Extends Beyond Equity Stake
The equity investment is accompanied by two separate clinical-development arrangements between Summit and AstraZeneca, both centered on combining ivonescimab with AstraZeneca's oncology portfolio.
Under the first agreement, the companies will evaluate ivonescimab in combination with AstraZeneca's Claudin 18.2-targeting antibody-drug conjugate (ADC), sonesitatug vedotin (sone-ve), for gastrointestinal cancers. The companies intend to initiate clinical studies of the combination imminently.
The companies have also signed a non-binding memorandum of understanding for a broader global development program that would evaluate ivonescimab in combination with multiple AstraZeneca cancer medicines, including additional ADCs.
Importantly, the arrangements are non-exclusive, with each company retaining its existing development and commercial rights to its respective molecule. For the combination studies, the companies will contribute their respective medicines and jointly share the costs of clinical development.
SMMT’s Stock Performance
Year to date, the company’s shares have lost about 12% compared with the industry’s 4% decline.
Image Source: Zacks Investment Research
Deal Gives Summit More Financial Flexibility
The $2 billion investment should significantly strengthen Summit's balance sheet as it expands the development of ivonescimab. The company had about $691 million in cash and short-term investments as of June 30, 2026, meaning the AstraZeneca investment is nearly three times its existing liquidity.
The additional funds are expected to give Summit greater flexibility to fund multiple clinical programs and reduce its near-term reliance on the capital markets. The transaction also provides a notable external endorsement of Summit's strategy, although the investment does not eliminate the clinical and regulatory risks associated with ivonescimab. The conversion would not only increase SMMT’s share count but also result in dilution for existing shareholders.
For AstraZeneca, the deal provides an opportunity to test ivonescimab alongside its own oncology portfolio, without acquiring Summit or obtaining exclusive rights to ivonescimab.
Summit’s Progress With Ivonescimab
Ivonescimab is a bispecific antibody designed to simultaneously target PD-1 and VEGF, two pathways that are already established targets in cancer treatment. The drug was originally developed by Akeso, with Summit holding exclusive development and commercialization rights across major markets outside China. Akeso retains the rights to market the drug in China, where it is currently approved to treat multiple non-small cell lung cancer (NSCLC) indications.
An FDA filing is currently under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment. A final decision is expected by Nov. 14, 2026.
Summit is pursuing a broad global development program for ivonescimab. It is advancing the drug across multiple phase III studies — HARMONi-3 in first-line metastatic NSCLC, HARMONi-7 in first-line metastatic PD-L1 high (≥50%) NSCLC and HARMONi-GI3 in first-line metastatic colorectal cancer. Last month, the company initiated the phase II/III HARMONi-GU1 study, evaluating ivonescimab plus Pfizer’s (PFE - Free Report) /Astellas’ Padcev as first-line treatment for advanced urothelial or bladder cancer.
Summit Therapeutics PLC Price
Summit Therapeutics PLC price | Summit Therapeutics PLC Quote
SMMT’s Zacks Rank
Summit currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.